Adicet Bio Inc (ACET) Institutional Buying & Selling Tracker (Q2 2026)

ACET ranks #5872 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ACET is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

56 institutions disclose a position in ACET, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 1.0% of its own portfolio to it.

Ken Griffin has added to its ACET position for two straight quarters, increasing it by $3.1M to reach $4.0M today.

Morgan Stanley has trimmed its ACET position for two straight quarters, cutting it by $5.8K while still holding $19.8K.

ACET is down 0% today, but institutions show net buying of $3.5M this quarter — a divergence between today's price move and the underlying institutional flow.

ACET reported a net loss of $116.8M in its latest fiscal year.

• Not yet profitable — net loss of $116.8M in the latest fiscal year
• Net income improved year over year, from -$117.1M to -$116.8M
• Operating cash flow was negative, using $95.2M in cash
• Current ratio of 7.47x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.21x equity — within a conventional range